Search

A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center.

… Wednesday, September 27, 2006 A gift from the estate of renowned fashion designer Geoffrey Beene will enable Memorial Sloan Kettering Cancer Center (MSKCC) to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center . It will build on MSKCC’s strong existing scientific

Learn how MSK is Improving patients’ quality of life with less toxic treatments.

… Monday, June 10, 2024 Marc Scarduffa was blindsided when he learned he had stage 3 rectal cancer. Fit and strong as he celebrated his 50th birthday, he had scheduled a colonoscopy simply because he knew he had reached the recommended age to begin screening for colorectal cancer (the recommended age has

A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.

… Thursday, January 22, 2015 Summary A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells. Stem cell therapy for Parkinson’s disease has shown great promise in animal studies and is moving closer to becoming an option for people

Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award.

… Tuesday, October 4, 2022 Today Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award. Dr. Gitlin was chosen for his outstanding work and proposal

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.

… Monday, February 15, 2021 Update: On August 11, 2021, the FDA approved pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for first-line treatments for patients with advanced renal cell carcinoma (RCC). Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

… Tuesday, October 22, 2019 Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

… Monday, April 20, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are reporting exciting results in the field of cancer immunology. Positive results from a clinical trial published today in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab

Diane Reidy-Lagunes sits down with Mary Elizabeth Williams to discuss what it was like being part of a phase 1 clinical trial, how clear communication can affect health outcomes, how guilt often accompanies survival, and what not to say to a cancer patient.

… Monday, November 29, 2021 When Mary Elizabeth Williams was diagnosed with stage 4 melanoma, she says: “My identity and my relationship with my mortality changed. That was the beginning of my new life.” Her decision to publicly disclose her diagnosis soon after receiving it was easy, she says. “I went

Data from 25,000 patients is helping scientists answer this and many other important questions.

… Thursday, February 3, 2022 Several years ago, in a lab meeting, one of Nikolaus Schultz’s postdoctoral fellows posed a question: “Do you think it’s possible to predict, based on the genomic profile of an individual tumor, which organs it might metastasize to?” And just like that, a research project was

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS, President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD, Associate Member of the Immunology Program at the Sloan Kettering Institute will be honored at the 2023 American Association for Cancer Research (AACR) Annual Meeting for their significant contributions to cancer research and care.

… Friday, April 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS , President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD , Associate Member of the Immunology Program at the Sloan Kettering Institute will be honored at the